Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

sampatrilat

Known as: N-(1-(2-carboxy-3-(N(2)-mesyllysylamino)propyl)-1-cyclopentylcarbonyl)tyrosine 
 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (3)

MesylatesProtease InhibitorsTyrosine

Narrower (1)

UK 81,252
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Whey-Derived Peptides Interactions with ACE by Molecular Docking as a Potential Predictive Tool of Natural ACE Inhibitors
Several milk/whey derived peptides possess high in vitro angiotensin I-converting enzyme (ACE) inhibitory activity. However, in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2018
2018
Crystal structures of sampatrilat and sampatrilat‐Asp in complex with human ACE – a molecular basis for domain selectivity
Angiotensin‐1‐converting enzyme (ACE) is a zinc metallopeptidase that consists of two homologous catalytic domains (known as nACE… Expand
Is this relevant?
2016
2016
The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme
Sampatrilat is a vasopeptidase inhibitor that inhibits both angiotensin I-converting enzyme (ACE) and neutral endopeptidase. ACE… Expand
Is this relevant?
2003
2003
Beneficial Effects of Sampatrilat, a Novel Vasopeptidase Inhibitor, on Cardiac Remodeling and Function of Rats with Chronic Heart Failure following Left Coronary Artery Ligation
Sampatrilat is a novel vasopeptidase inhibitor that may offer a greater benefit than traditional angiotensin-converting enzyme… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2002
2002
Sampatrilat Shire.
Sampatrilat is a dual inhibitor of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE), which is under… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.
Our objective was to evaluate the safety and antihypertensive efficacy of sampatrilat, a novel dual inhibitor of both angiotensin… Expand
Is this relevant?
1998
1998
Combined inhibition of neutral endopeptidase and angiotensin‐converting enzyme by sampatrilat in essential hypertension
The antihypertensive response to angiotensin‐converting enzyme (ACE) inhibitors may be attenuated by a compensatory decrease in… Expand
Is this relevant?
1998
1998
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide…
Sampatrilat is a dual inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) under development for the… Expand
Is this relevant?
1998
1998
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass…
Sampatrilat is a dual inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) under development for the… Expand
Is this relevant?
1996
1996
Renal effects of concurrent E‐24.11 and ACE inhibition in the aorto‐venocaval fistula rat
1 The present studies compare the early renal response to (a) an endopeptidase‐24.11 (E‐24.11) inhibitor (candoxatrilat) (b) an… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE